We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MAMK:NASDAQMaxsMaking Inc. Analysis

Data as of 2026-05-24 - not real-time

$13.16

Latest Price

8/10Risk

Risk Level: High

Executive Summary

MaxsMaking Inc. is trading at $13.16, just above its 20‑day and 50‑day SMAs but well above the 200‑day SMA of $9.69, indicating a modest upward bias. However, the 14‑day RSI of 80.8 signals an overbought condition, and the MACD histogram is negative with a bearish signal line, suggesting short‑term downside pressure. The stock’s valuation is extreme, with a trailing P/E of 219 versus an industry average of 29.7, and a price‑to‑book ratio near 18, highlighting significant overvaluation. Fundamental metrics are weak: profit margin is essentially zero, operating cash flow is -$5.3 M, free cash flow -$4.5 M, and debt‑to‑equity stands at 34.3, while revenue growth remains robust at 44%. The company’s beta of -0.1 and 30‑day volatility of 0% mask underlying risk, as evidenced by a historic max drawdown of 46.6% and a market cap of only $219 M, implying limited liquidity.
Given the combination of an overbought technical setup, bearish momentum, severe overvaluation, negative cash generation, and high leverage, the outlook remains cautious. The lack of dividend and a “none” analyst consensus further diminish appeal. Investors should weigh the strong revenue growth against the deteriorating profitability and balance‑sheet pressures before deciding on exposure.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • RSI over 80 indicating overbought conditions
  • Bearish MACD histogram
  • Price at immediate resistance level

Medium Term

1–3 years
Cautious
Model confidence: 8/10

Key Factors

  • Extreme P/E relative to industry
  • Negative operating and free cash flow
  • High debt‑to‑equity ratio

Long Term

> 3 years
Cautious
Model confidence: 6/10

Key Factors

  • Sustained revenue growth not translating to profitability
  • Significant max drawdown history
  • Limited liquidity and small market cap

Key Metrics & Analysis

Financial Health

Revenue Growth43.70%
Profit Margin0.01%
P/E Ratio219.3
ROE0.17%
ROA0.33%
Debt/Equity34.30
P/B Ratio17.8
Op. Cash Flow$-5285745
Free Cash Flow$-4540143
Industry P/E29.7

Technical Analysis

TrendNeutral
RSI80.8
Support$13.00
Resistance$13.00
MA 20$13.00
MA 50$13.00
MA 200$9.69
MACDBearish
VolumeStable
Fear & Greed Index91.61

Valuation

GradeOvervalued
TypeGrowth

Risk Assessment

Beta-0.10
0
Sector RiskMedium
Reg. RiskMedium
Geo RiskHigh
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.